2.14
Perspective Therapeutics Inc stock is traded at $2.14, with a volume of 841.60K.
It is up +11.46% in the last 24 hours and down -15.08% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$1.92
Open:
$1.95
24h Volume:
841.60K
Relative Volume:
1.10
Market Cap:
$154.77M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-12.47
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+2.39%
1M Performance:
-15.08%
6M Performance:
-82.73%
1Y Performance:
-86.01%
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CATX
Perspective Therapeutics Inc
|
2.14 | 154.77M | 6.96M | -46.51M | -37.99M | -0.1716 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-25 | Initiated | H.C. Wainwright | Buy |
Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
Oct-24-24 | Initiated | UBS | Buy |
Oct-01-24 | Initiated | Wedbush | Outperform |
Sep-25-24 | Initiated | Truist | Buy |
Jul-25-24 | Initiated | BofA Securities | Buy |
May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | CATX Stock News - GuruFocus
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Announce Q1 2025 Financial Results and Business Update on May 12, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial - Bluefield Daily Telegraph
Perspective Therapeutics Q1 2025 Earnings: Key Business Updates Coming May 12What to Watch - Stock Titan
Arrowstreet Capital Limited Partnership Has $117,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
KLP Kapitalforvaltning AS Invests $79,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - MarketBeat
Perspective Therapeutics (PSTH) Advances Trial for Melanoma Trea - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with [212 - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy - MarketScreener
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - MarketScreener
Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial - Stock Titan
Is Now The Time To Invest In Perspective Therapeutics? (NYSE:CATX) - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) Given New $10.00 Price Target at Truist Financial - Defense World
Truist cuts Perspective Therapeutics target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist cuts Perspective Therapeutics target to $10, maintains Buy - Investing.com
Paraganglioma Treatment Market Size in 7MM is expected to grow - openPR.com
Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating - marketscreener.com
CATX stock touches 52-week low at $1.87 amid market challenges - Investing.com Australia
CATX stock touches 52-week low at $1.87 amid market challenges By Investing.com - Investing.com South Africa
What is HC Wainwright’s Estimate for CATX Q2 Earnings? - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Pheochromocytomas and Paragangliomas Treatment Market Size - openPR.com
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective Therapeutics director Robert Williamson buys $132,151 in stock - Investing.com Australia
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock - Investing.com Australia
Perspective Therapeutics director Lori Woods acquires $49,999 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com South Africa
Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com India
Perspective Therapeutics (NYSE:CATX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World
Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times
Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan
Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World
CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World
HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World
Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com
Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cap:
|
Volume (24h):